for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

CSPC Pharmaceutical Group Ltd

1093.HK

Latest Trade

16.96HKD

Change

-0.06(-0.35%)

Volume

29,495,727

Today's Range

16.72

 - 

17.18

52 Week Range

9.90

 - 

21.80

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
17.02
Open
16.92
Volume
29,495,727
3M AVG Volume
800.19
Today's High
17.18
Today's Low
16.72
52 Week High
21.80
52 Week Low
9.90
Shares Out (MIL)
6,236.34
Market Cap (MIL)
111,879.90
Forward P/E
25.67
Dividend (Yield %)
1.00

Next Event

Full Year 2019 CSPC Pharmaceutical Group Ltd Earnings Release

Latest Developments

More

CSPC Pharmaceutical Says Cefixime Capsules (0.1G) Granted Approval By NMPA

CSPC Pharmaceutical Group Says 9-Month Profit Attributable RMB2.81 Bln

CSPC Pharmaceutical Announces Passing Of Consistency Evaluation For "Cephalexin Capsules"

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About CSPC Pharmaceutical Group Ltd

CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs). All these segments are engaged in the manufacture and sales of related pharmaceutical products. The finished drugs include the antibiotics, cardio-cerebrovascular drugs, diabetes drugs, neurology drugs, oncology drugs and traditional Chinese medicines. The Company is also engaged in the provision of pharmaceutical research and development services, as well as the processing of sewage and pharmaceutical by-products through its subsidiaries.

Industry

Biotechnology & Drugs

Contact Info

No. 226 Huanghe Avenue

+86.311.87037015

http://www.cspc.com.hk/

Executive Leadership

Dongchen Cai

Executive Chairman of the Board, Chief Executive Officer

Cuilong Zhang

Executive Vice Chairman of the Board, Rotating Chief Executive Officer

Kin Man Chak

Executive Director

Chunlei Li

Executive Director

Hua Lu

Executive Director

Key Stats

1.70 mean rating - 30 analysts
Sell
Hold
Buy
Revenue (MM, HKD)

2016

12.4K

2017

15.5K

2018

21.0K

2019(E)

25.3K
EPS (HKD)

2016

0.350

2017

0.455

2018

0.586

2019(E)

0.693
Price To Earnings (TTM)
27.74
Price To Sales (TTM)
4.72
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
23.20
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

BRIEF-CSPC Pharmaceutical Announces A Product Licensing Agreement

* UNIT ENTERED PRODUCT LICENSING AGREEMENT WITH GALAXY BIO, INC. FOR LICENSING & COMMERCIALIZATION OF "PACLITAXEL FOR INJECTION"

BRIEF-CSPC Pharmaceutical Group Says Cancer Drug Approved By China FDA

* "VINORELBINE TARTRATE LIPOSOME INJECTION" GRANTED CLINICAL TRIAL APPROVAL BY CHINA FOOD AND DRUG ADMINISTRATION OF PRC Source text for Eikon: Further company coverage:

BRIEF-CSPC Pharmaceutical Group's Drug Gets Approval By China FDA

* GRANTED APPROVAL BY CHINA FDA FOR PASSING CONSISTENCY OF QUALITY AND EFFICACY EVALUATION OF GENERIC DRUGS

BRIEF-CSPC Pharmaceutical Group Says ‍Cancer Drug Granted Drug Clinical Trial Approval By China FDA

* CANCER DRUG DEVELOPED BY WUHAN YZY BIOPHARMA GRANTED DRUG CLINICAL TRIAL APPROVAL BY CHINA FDA Source text for Eikon: Further company coverage:

BRIEF-CSPC Pharmaceutical Group Announces Drug Registration Approval Of "Paclitaxel For Injection (Albumin-Bound)"

* "PACLITAXEL FOR INJECTION (ALBUMIN-BOUND)" GRANTED DRUG REGISTRATION APPROVAL BY CHINA FOOD AND DRUG ADMINISTRATION Source text for Eikon: Further company coverage:

BRIEF-CSPC Pharmaceutical Group's Gastric Cancer Drug Granted Orphan-Drug Designation By U.S. FDA​

* GROUP'S GASTRIC CANCER DRUG "DP303C" WAS GRANTED ORPHAN-DRUG DESIGNATION BY U.S. FDA Source text for Eikon: Further company coverage:

BRIEF-CSPC Pharmaceutical Group Says Unit's Listing Application To CSRC Was Accepted

* CSPC XNW SUBMITTED APPLICATION TO CSRC FOR PROPOSED A SHARE LISTING ON CHINEXT OF SZSE & RECEIVED NOTICE OF ACCEPTANCE

BRIEF-CSPC Pharmaceutical Group Appoints ‍Li Chunlei As Executive Director ​

* LI CHUNLEI WAS APPOINTED AS AN EXECUTIVE DIRECTOR OF COMPANY WITH EFFECT FROM 12 DECEMBER 2017.

BRIEF-CSPC Pharmaceutical Group announces change of shareholdings of substantial shareholder

* Massive Giant Group transferred approximately 6.78% of total issued shares to Common Success International Source text for Eikon: Further company coverage:

BRIEF-CSPC Pharmaceutical Group posts 9-month profit attributable of HK$‍2.04​ bln

* 9-month profit attributable HK$2.04 billion versus HK$1.57 billion

BRIEF-CSPC Pharmaceutical Group updates on approvals ​of granted clinical trial

* Group's "HA121-28" and "alprostadil liposome injection" were granted clinical trial approvals

BRIEF-CSPC Pharmaceutical Group ‍to issue 189 mln placing shares at HK$12.44 per share​

* shall issue 189 million placing shares at placing price of hk$12.44 per share

BRIEF-CSPC Pharmaceutical Group updates on trading halt

* seeks trading halt pending release of announcement regarding placing of new shares under general mandate Source text for Eikon: Further company coverage:

BRIEF-CSPC Pharmaceutical says‍ trading in shares of co has been halted

* Trading in shares of co has been halted at 9:08 a.m. on oct 12 Source text for Eikon: Further company coverage:

BRIEF-CSPC Pharmaceutical Group's unit buys 1.31 PCT stake in CSPC Innovation Pharmaceutical

* Unit announces acquisition of 1.31 percent stake in CSPC Innovation Pharmaceutical Co for RMB 9.4 million

BRIEF-CSPC Pharmaceutical Group receives U.S.FDA orphan-drug designation for malignant tumour treatment drug

* Group's Malignant Tumour Treatment Drug "Mitoxantrone Hydrochloride Liposome' was granted orphan-drug designation by the U.S. FDA

BRIEF-Gemdale Properties and Investment Corp announces on group's aggregate contracted sales for July

* Group's aggregate contracted sales for July 2017 amounted to approximately RMB3,003 million Source text for Eikon: Further company coverage:

BRIEF-CSPC Pharmaceutical appoints vice-chairman and rotating CEO

* Pan Waidong has been appointed as vice-chairman and rotating chief executive officer of company Source text for Eikon: Further company coverage:

BRIEF-CSPC Pharmaceutical announces retirement of executive director

* Wang Shunlong retired from office as executive director of company Source text for Eikon: Further company coverage:

BRIEF-CSPC Pharmaceutical Group says qtrly profit attributable HK$ 637.9 mln vs HK$505.6 mln

* Qtrly profit attributable hk$ 637.9 million versus hk$505.6 million

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up